EXAS
Price
$53.81
Change
+$2.40 (+4.67%)
Updated
Sep 5 closing price
Capitalization
10.19B
53 days until earnings call
PRPO
Price
$17.74
Change
+$1.64 (+10.19%)
Updated
Sep 5 closing price
Capitalization
28.73M
Interact to see
Advertisement

EXAS vs PRPO

Header iconEXAS vs PRPO Comparison
Open Charts EXAS vs PRPOBanner chart's image
Exact Sciences
Price$53.81
Change+$2.40 (+4.67%)
Volume$4.19M
Capitalization10.19B
Precipio
Price$17.74
Change+$1.64 (+10.19%)
Volume$33.31K
Capitalization28.73M
EXAS vs PRPO Comparison Chart in %
Loading...
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRPO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXAS vs. PRPO commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXAS is a StrongBuy and PRPO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (EXAS: $53.81 vs. PRPO: $17.74)
Brand notoriety: EXAS: Notable vs. PRPO: Not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: EXAS: 131% vs. PRPO: 229%
Market capitalization -- EXAS: $10.19B vs. PRPO: $28.73M
EXAS [@Medical Specialties] is valued at $10.19B. PRPO’s [@Medical Specialties] market capitalization is $28.73M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $10.68B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXAS’s FA Score shows that 0 FA rating(s) are green whilePRPO’s FA Score has 1 green FA rating(s).

  • EXAS’s FA Score: 0 green, 5 red.
  • PRPO’s FA Score: 1 green, 4 red.
According to our system of comparison, PRPO is a better buy in the long-term than EXAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXAS’s TA Score shows that 4 TA indicator(s) are bullish while PRPO’s TA Score has 4 bullish TA indicator(s).

  • EXAS’s TA Score: 4 bullish, 5 bearish.
  • PRPO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PRPO is a better buy in the short-term than EXAS.

Price Growth

EXAS (@Medical Specialties) experienced а +13.48% price change this week, while PRPO (@Medical Specialties) price change was +14.30% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.01%. For the same industry, the average monthly price growth was +8.25%, and the average quarterly price growth was +13.64%.

Reported Earning Dates

EXAS is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Medical Specialties (+1.01% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXAS($10.2B) has a higher market cap than PRPO($28.7M). PRPO YTD gains are higher at: 220.228 vs. EXAS (-4.236). PRPO has higher annual earnings (EBITDA): -93K vs. EXAS (-758.48M). EXAS has more cash in the bank: 858M vs. PRPO (1.13M). PRPO has less debt than EXAS: PRPO (2.61M) vs EXAS (2.52B). EXAS has higher revenues than PRPO: EXAS (2.94B) vs PRPO (21.2M).
EXASPRPOEXAS / PRPO
Capitalization10.2B28.7M35,540%
EBITDA-758.48M-93K815,571%
Gain YTD-4.236220.228-2%
P/E RatioN/AN/A-
Revenue2.94B21.2M13,868%
Total Cash858M1.13M75,929%
Total Debt2.52B2.61M96,553%
FUNDAMENTALS RATINGS
EXAS vs PRPO: Fundamental Ratings
EXAS
PRPO
OUTLOOK RATING
1..100
146
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
31
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
5536
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRPO's Valuation (31) in the Biotechnology industry is in the same range as EXAS (40). This means that PRPO’s stock grew similarly to EXAS’s over the last 12 months.

PRPO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EXAS (100). This means that PRPO’s stock grew similarly to EXAS’s over the last 12 months.

PRPO's SMR Rating (95) in the Biotechnology industry is in the same range as EXAS (97). This means that PRPO’s stock grew similarly to EXAS’s over the last 12 months.

PRPO's Price Growth Rating (36) in the Biotechnology industry is in the same range as EXAS (55). This means that PRPO’s stock grew similarly to EXAS’s over the last 12 months.

PRPO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as EXAS (100). This means that PRPO’s stock grew similarly to EXAS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXASPRPO
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
80%
Declines
ODDS (%)
Bearish Trend 27 days ago
81%
Bearish Trend 13 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRPO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EVAV25.140.67
+2.76%
Direxion Dl Elctrc&Atnms vhcls Bull2XETF
VLT11.190.02
+0.18%
Invesco High Income Trust II
USTB51.100.05
+0.10%
VictoryShares Short-Term Bond ETF
JUNP29.55-0.02
-0.06%
PGIM S&P 500 Buffer 12 ETF - Jun
BCD33.47-0.09
-0.28%
abrdn Blmb AllCmdLDSK1Fr ETF

EXAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with ILMN. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then ILMN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAS
1D Price
Change %
EXAS100%
+4.67%
ILMN - EXAS
37%
Loosely correlated
+1.28%
RVTY - EXAS
33%
Loosely correlated
+1.10%
XRAY - EXAS
33%
Poorly correlated
+2.02%
A - EXAS
33%
Poorly correlated
+0.21%
SNN - EXAS
32%
Poorly correlated
+1.20%
More

PRPO and

Correlation & Price change

A.I.dvisor tells us that PRPO and TLSI have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PRPO and TLSI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRPO
1D Price
Change %
PRPO100%
+10.19%
TLSI - PRPO
23%
Poorly correlated
-3.11%
OPK - PRPO
21%
Poorly correlated
-2.17%
EXAS - PRPO
21%
Poorly correlated
+4.67%
TNON - PRPO
20%
Poorly correlated
+2.61%
MYO - PRPO
10%
Poorly correlated
-1.21%
More